Roth Mkm upgraded shares of Inseego (NASDAQ:INSG – Free Report) from a neutral rating to a buy rating in a report issued on Thursday, Marketbeat reports. They currently have $15.00 price target on the technology company’s stock, up from their previous price target of $13.00.
Several other equities analysts have also issued reports on the company. Stifel Nicolaus boosted their price objective on Inseego from $11.00 to $17.00 and gave the company a “hold” rating in a research report on Tuesday, September 17th. TD Cowen upped their price target on shares of Inseego from $13.50 to $15.00 and gave the company a “hold” rating in a report on Wednesday, August 14th.
Inseego Trading Down 3.5 %
Institutional Investors Weigh In On Inseego
Hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new position in Inseego during the 3rd quarter worth approximately $26,000. Covestor Ltd acquired a new position in Inseego during the third quarter worth $32,000. Barclays PLC boosted its holdings in Inseego by 71.3% during the third quarter. Barclays PLC now owns 4,051 shares of the technology company’s stock worth $67,000 after purchasing an additional 1,686 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Inseego in the third quarter valued at $73,000. Finally, Olympiad Research LP acquired a new stake in Inseego in the 3rd quarter valued at $184,000. Institutional investors and hedge funds own 34.20% of the company’s stock.
Inseego Company Profile
Inseego Corp. engages in the design and development of cloud-managed wireless wide area network (WAN) and intelligent edge solutions for businesses, consumers, and governments worldwide. The company provides 5G and 4G mobile broadband solutions, such as mobile hotspots under the MiFi brand; and 4G VoLTE products and 4G USB modems.
See Also
- Five stocks we like better than Inseego
- Quiet Period Expirations Explained
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- How to Invest in Biotech Stocks
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is the Dogs of the Dow Strategy? Overview and Examples
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Inseego Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inseego and related companies with MarketBeat.com's FREE daily email newsletter.